| Study participants n = 391 | Non-survivors n = 234 | Survivors n = 157 | Descriptive p-value (unadjusted)a |
---|---|---|---|---|
Antifungal strategy | Â | Â | Â | 0.128 |
 Targeted b | 174 (44.5%) | 96 (41.0%) | 78 (49.7%) |  |
 Empirical c | 88 (22.5%) | 53 (22.6%) | 35 (22.3%) |  |
 Resistant d | 8 (2.0%) | 3 (1.3%) | 5 (3.2%) |  |
 Delayed e | 14 (3.6%) | 8 (3.4%) | 6 (3.8%) |  |
 None | 107 (27.4%) | 74 (31.6%) | 33 (21.0%) |  |
Treatment with echinocandin | 187 (47.8%) | 108 (46.2%) | 79 (50.3%) | 0.419 |
Empirical therapy c | Â | Â | Â | 0.435 |
 Echinocandin | 41 (10.5%) | 24 (10.3%) | 17 (10.8%) |  |
 Azoles | 48 (12.3%) | 32 (13.7%) | 16 (10.2%) |  |
 Amphotericin B | 6 (1.5%) | 2 (0.9%) | 4 (2.5%) |  |
Duration of antifungal treatment (days) | 8 (0–17) | 5 (0–15) | 11 (3–19) |  < 0.001 |
Antifungals f | ||||
 Fluconazole | 159 (40.7) | 83 (35.5) | 76 (48.4) |  |
 Anidulafungin | 129 (33.0) | 75 (32.1) | 54 (34.4) |  |
 Caspofungin | 66 (16.9) | 37 (15.8) | 29 (18.5) |  |
 Voriconazole | 22 (5.6) | 18 (7.7) | 4 (2.5) |  |
 Amphotericin B | 16 (4.1) | 8 (3.4) | 8 (5.1) |  |
 Posaconazole | 1 (0.3) | 1 (0.4) | 0 (0) |  |
 Itraconazole | 1 (0.3) | 1 (0.4) | 0 (0) |  |